Artelo Biosciences (ARTL) Competitors $9.00 -0.48 (-5.06%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$10.50 +1.50 (+16.67%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. MIRA, RNTX, JATT, NNVC, BDRX, TENX, CASI, AYTU, QTTB, and LGVNShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include MIRA Pharmaceuticals (MIRA), Rein Therapeutics (RNTX), JATT Acquisition (JATT), NanoViricides (NNVC), Biodexa Pharmaceuticals (BDRX), Tenax Therapeutics (TENX), CASI Pharmaceuticals (CASI), Aytu BioPharma (AYTU), Q32 Bio (QTTB), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Its Competitors MIRA Pharmaceuticals Rein Therapeutics JATT Acquisition NanoViricides Biodexa Pharmaceuticals Tenax Therapeutics CASI Pharmaceuticals Aytu BioPharma Q32 Bio Longeveron MIRA Pharmaceuticals (NASDAQ:MIRA) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk. Which has stronger earnings and valuation, MIRA or ARTL? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-2.80Artelo BiosciencesN/AN/A-$9.83M-$17.94-0.50 Does the media prefer MIRA or ARTL? In the previous week, Artelo Biosciences had 5 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 7 mentions for Artelo Biosciences and 2 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.26 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artelo Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in MIRA or ARTL? 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is MIRA or ARTL more profitable? Artelo Biosciences' return on equity of -226.99% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -341.08% -272.93% Artelo Biosciences N/A -226.99%-164.61% Do analysts prefer MIRA or ARTL? MIRA Pharmaceuticals currently has a consensus price target of $17.00, suggesting a potential upside of 1,088.81%. Artelo Biosciences has a consensus price target of $24.00, suggesting a potential upside of 166.67%. Given MIRA Pharmaceuticals' higher probable upside, equities analysts clearly believe MIRA Pharmaceuticals is more favorable than Artelo Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.60 Which has more risk & volatility, MIRA or ARTL? MIRA Pharmaceuticals has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. SummaryMIRA Pharmaceuticals and Artelo Biosciences tied by winning 7 of the 14 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.68M$3.01B$5.56B$9.47BDividend YieldN/A2.41%4.31%4.17%P/E Ratio-0.5016.5729.3723.99Price / SalesN/A313.98444.7496.71Price / CashN/A42.1735.8458.51Price / Book1.697.818.085.58Net Income-$9.83M-$54.52M$3.26B$265.35M7 Day Performance-24.11%0.41%0.44%-0.07%1 Month Performance-37.15%9.93%4.82%1.76%1 Year Performance12.78%15.18%30.27%25.39% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.0513 of 5 stars$9.00-5.1%$24.00+166.7%+11.9%$6.68MN/A-0.505Positive NewsUpcoming EarningsAnalyst ForecastShort Interest ↑MIRAMIRA Pharmaceuticals2.2431 of 5 stars$1.55-1.5%$17.00+999.6%-37.3%$26.31MN/A-3.052Upcoming EarningsRNTXRein TherapeuticsN/A$1.14+1.7%N/AN/A$26.26MN/A-0.409News CoverageJATTJATT AcquisitionN/A$1.50+7.1%N/A-57.3%$25.88MN/A0.003High Trading VolumeNNVCNanoViricides0.497 of 5 stars$1.59-0.3%N/A-22.8%$25.62MN/A-2.2120BDRXBiodexa Pharmaceuticals0.0813 of 5 stars$7.00+0.2%N/AN/A$25.53M$470K0.0020News CoverageShort Interest ↑TENXTenax Therapeutics1.3201 of 5 stars$6.01-2.8%$17.50+191.4%+62.5%$24.91MN/A-2.429Upcoming EarningsCASICASI Pharmaceuticals3.9745 of 5 stars$1.93-1.3%$4.00+107.8%-73.7%$24.17M$31.37M-0.77180News CoverageAYTUAytu BioPharma3.1995 of 5 stars$2.63-0.8%$10.00+280.2%-2.0%$23.62M$81M-3.65160QTTBQ32 Bio2.2738 of 5 stars$1.94+0.3%$12.17+528.8%-94.7%$23.61M$1.16M-0.3939News CoverageShort Interest ↑Gap DownLGVNLongeveron2.6866 of 5 stars$1.57-8.5%$8.67+453.8%-48.3%$23.37M$2.39M-0.2520Upcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies MIRA Pharmaceuticals Alternatives Rein Therapeutics Alternatives JATT Acquisition Alternatives NanoViricides Alternatives Biodexa Pharmaceuticals Alternatives Tenax Therapeutics Alternatives CASI Pharmaceuticals Alternatives Aytu BioPharma Alternatives Q32 Bio Alternatives Longeveron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
